These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30848293)

  • 1. Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute.
    Siedler A; Koch J; Garbe E; Hengel H; von Kries R; Ledig T; Mertens T; Zepp F; Überla K
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2019 Mar; 62(3):352-376. PubMed ID: 30848293
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany.
    Préaud E; Uhart M; Böhm K; Aidelsburger P; Anger D; Bianic F; Largeron N
    Hum Vaccin Immunother; 2015; 11(4):884-96. PubMed ID: 25933182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunizations in immunocompromised patients: a guide for dermatologists.
    Mohme S; Schmalzing M; Müller CSL; Vogt T; Goebeler M; Stoevesandt J
    J Dtsch Dermatol Ges; 2020 Jul; 18(7):699-723. PubMed ID: 32713146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Role, working methods and recommendations of the Standing Committee on Vaccinations (STIKO) in the context of the COVID-19 pandemic].
    Vygen-Bonnet S; Schlaberg J; Koch J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2022 Dec; 65(12):1251-1261. PubMed ID: 36416888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Vaccination in older adults: compulsory or voluntary exercise?].
    Kwetkat A; Endres AS; Leischker A; Heppner HJ
    Dtsch Med Wochenschr; 2020 Aug; 145(16):1133-1137. PubMed ID: 32791548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The German Standing Committee on Vaccination: organization and mode of functioning].
    Harder T
    Z Rheumatol; 2020 Nov; 79(9):839-847. PubMed ID: 32902696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine.
    Grupping K; Campora L; Douha M; Heineman TC; Klein NP; Lal H; Peterson J; Vastiau I; Oostvogels L
    J Infect Dis; 2017 Dec; 216(11):1343-1351. PubMed ID: 29029122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
    Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
    J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the impact of combined vaccination programs against varicella and herpes zoster in Norway.
    Marchetti S; Guzzetta G; Flem E; Mirinaviciute G; Scalia Tomba G; Manfredi P
    Vaccine; 2018 Feb; 36(8):1116-1125. PubMed ID: 29366704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults.
    Chlibek R; Pauksens K; Rombo L; van Rijckevorsel G; Richardus JH; Plassmann G; Schwarz TF; Catteau G; Lal H; Heineman TC
    Vaccine; 2016 Feb; 34(6):863-8. PubMed ID: 26432913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Vaccination recommendations of the Standing Committee on Vaccination at the Robert Koch Institute. Legal basis and significance].
    Schaade L; Widders U; Stange G; Höhl N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Nov; 52(11):1006-10. PubMed ID: 19768391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Revaccination against pertussis. Recommendations from STIKO (Standing Vaccination Commission of the Robert Koch Institute)].
    Zepp F;
    Med Monatsschr Pharm; 2001 Feb; 24(2):51-3. PubMed ID: 11255986
    [No Abstract]   [Full Text] [Related]  

  • 15. Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany.
    Matysiak-Klose D; Santibanez S; Schwerdtfeger C; Koch J; von Bernuth H; Hengel H; Littmann M; Terhardt M; Wicker S; Mankertz A; Heininger U
    Vaccine; 2018 Dec; 36(52):7916-7922. PubMed ID: 30478003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany - a mathematical modelling study.
    Horn J; Damm O; Greiner W; Hengel H; Kretzschmar ME; Siedler A; Ultsch B; Weidemann F; Wichmann O; Karch A; Mikolajczyk RT
    BMC Med; 2018 Jan; 16(1):3. PubMed ID: 29316913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated influenza virus vaccine in the therapy of herpes zoster; clinical evaluation.
    GRISWOLD CM; BOWEN SS
    Tex State J Med; 1953 Sep; 49(9):693-5. PubMed ID: 13102361
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
    Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
    Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of vaccination of immunocompetent older adults against herpes zoster in the Netherlands: a comparison between the adjuvanted subunit and live-attenuated vaccines.
    de Boer PT; van Lier A; de Melker H; van Wijck AJM; Wilschut JC; van Hoek AJ; Postma MJ
    BMC Med; 2018 Dec; 16(1):228. PubMed ID: 30518427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.